The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and morenews2026-02-07T11:00:05+00:00February 7th, 2026|Endpoints News|
Big Pharma earnings kick off; Third-round IRA drugs selected; Hengrui’s trailblazing moment; and morenews2026-01-31T11:00:35+00:00January 31st, 2026|Endpoints News|
First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and morenews2026-01-24T11:00:43+00:00January 24th, 2026|Endpoints News|
JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more news2026-01-17T11:00:32+00:00January 17th, 2026|Endpoints News|
US slashes vaccine schedule; Every drug approval from 2025; argenx’s new CEO; and morenews2026-01-10T11:00:00+00:00January 10th, 2026|Endpoints News|
Nine more MFN deals; Western drugmakers turn to China; Chai Discovery’s raise; and morenews2025-12-20T11:00:59+00:00December 20th, 2025|Endpoints News|
Eli Lilly’s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and morenews2025-12-13T11:00:18+00:00December 13th, 2025|Endpoints News|
ACIP vote, more FDA turnover; Introducing Endpoints Signal; ARCH, Parker Institute building next cancer bet; and morenews2025-12-06T11:00:06+00:00December 6th, 2025|Endpoints News|
Makary’s user fee comments; M&A activity stays hot; A new use for prime editing; and morenews2025-11-22T11:00:03+00:00November 22nd, 2025|Endpoints News|
Inside the Metsera bidding war; PD-(L)1xVEGF bispecific race heats up; Pazdur tapped as next CDER head; and morenews2025-11-15T11:00:13+00:00November 15th, 2025|Endpoints News|
